APPLIED THERAPEUTICS, INC.

Analyst Reco. Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.28 ^USD	+1.18%		-2.28%	+27.76%

Apr. 15	Applied Therapeutics, Inc. Announces Management Changes	CI
Mar. 28	Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Initiates Applied Therapeutics at Outperform, Speculative Risk With $12 Price Target, Sees Lead Drug Govorestat 'Well-Positioned for Success'	Mar. 26	MT
UBS Adjusts Applied Therapeutics Price Target to $13 From $12, Maintains Buy Rating	Mar. 15	MT
UBS Adjusts Applied Therapeutics Price Target to $12 From $4, Maintains Buy Rating	Mar. 06	MT
Leerink Partners Initiates Applied Therapeutics at Outperform Rating $12 Price Target	Feb. 22	MT
S&P 500, Nasdaq climb as fresh data boosts rate-cut bets again	Jan. 05	RE
US job data raises doubts about the Fed's next moves	Jan. 05
Waning Rate Cut Hopes, Employment Situation Report Push Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	Jan. 05	MT
Baird Adjusts Applied Therapeutics Price Target to $14 From $18, Maintains Outperform Rating	23-04-25	MT
Citigroup Adjusts Applied Therapeutics Price Target to $5 From $23, Maintains Buy Rating	23-04-05	MT
Citigroup Cuts Price Target on Applied Therapeutics to $23 From $29, Keeps Buy Rating	22-08-17	MT
Citigroup Adjusts Applied Therapeutics' Price Target to $29 from $30, Keeps Buy Rating	22-05-20	MT
Truist Securities Adjusts Price Target on Applied Therapeutics to $6 From $85, Reiterates Buy Rating	22-04-13	MT
Barclays Adjusts Price Target on Applied Therapeutics to $2.50 From $7, Keeps Equalweight Rating	22-03-21	MT
Citigroup Adjusts Applied Therapeutics' Price Target to $30 From $38, Reiterates Buy Rating	22-01-05	MT
Goldman Sachs Adjusts Price Target on Applied Therapeutics to $3 From $10, Reiterates Sell Rating	22-01-05	MT
Barclays Downgrades Applied Therapeutics to Equalweight From Overweight, Slashes Price Target to $7 From $44	22-01-04	MT
APPLIED THERAPEUTICS : Goldman Sachs Cuts Applied Therapeutics to Sell From Neutral, Price Target to $10 From $16	21-08-27	MT
APPLIED THERAPEUTICS : UBS Adjusts Price Target on Applied Therapeutics to $48 From $67 on Adjusted AT-001, AT-007 Timelines; Buy Rating Kept	21-02-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer